Immunology and clinical approach to adult-onset type 1 diabetes
DOI:
https://doi.org/10.69734/71yw1j63Keywords:
type 1 diabetes, insulin, autoantibodies, diabetic ketoacidosis, autoimmune, endotypes, B-cell, C-peptideAbstract
Misdiagnosis of type 1 diabetes (T1D) remains a significant clinical concern, often leading to delays in appropriate treatment to prevent its complications. Accurate and timely diagnosis is critical to optimize patient outcomes, yet distinguishing T1D from other forms of diabetes—particularly type 2—can be challenging, especially in adults. This review highlights the importance of precise and accurate diagnostic strategies by focusing on key clinical and biochemical markers, particularly the presence of islet autoantibodies (IAABs) and reduced C-peptide levels, which are indicative of autoimmune β-cell destruction characteristic of T1D. By synthesizing current literature-limited in some areas-, we evaluate diagnostic pathways that leverage these markers to improve diagnostic accuracy. Additionally, we discuss treatment approaches, emphasizing the central role of insulin therapy and the potential use of adjunctive therapies to enhance glycemic control. This review aims to provide clinicians with practical guidance to refine diagnosis and management of T1D, ultimately reducing the burden of misdiagnosis and improving long-term outcomes.
References
*** Smartphone users - scroll to the end of the References to view Article ***
American Diabetes A. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019 Jan.;42(Suppl 1):S13-28. DOI: 10.2337/dc19-S002.
Rogers MAM, Kim C, Banerjee T, Lee JM. Fluctuations in the incidence of type 1 diabetes in the United States from 2001 to 2015: a longitudinal study. BMC Med. 2017 Nov 8;15(1):199. DOI: 10.1186/s12916-017-0958-6.
Casu A, Kanapka LG, Foster NC, et al. Characteristics of adult- compared to childhood-onset type 1 diabetes. Diabet Med. 2020 Apr 30. DOI: 10.1111/dme.14314.
American Diabetes Association Professional Practice C. Diagnosis and classification of diabetes: standards of care in diabetes-2024. Diabetes Care. 2024 Jan 1;47(Suppl 1):S20-42. DOI: 10.2337/dc24-S002.
Fourlanos S, Perry C, Stein MS, Stankovich J, Harrison LC, Colman PG. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care. 2006 May;29(5):970-5. DOI: 10.2337/diacare.295970.
Thomas NJ, Lynam AL, Hill AV, et al. Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes. Diabetologia. 2019 Jul;62(7):1167-72. DOI: 10.1007/s00125-019-4863-8.
Jones AG, McDonald TJ, Shields BM, Hagopian W, Hattersley AT. Latent autoimmune diabetes of adults (LADA) is likely to represent a mixed population of autoimmune (type 1) and nonautoimmune (type 2) diabetes. Diabetes Care. 2021 Jun;44(6):1243-51. DOI: 10.2337/dc20-2834.
Fang M, Wang D, Echouffo-Tcheugui JB, Selvin E. Age at diagnosis in u.s. adults with type 1 diabetes. Ann Intern Med. 2023 Nov;176(11):1567-8. DOI: 10.7326/M23-1707.
Thomas NJ, Jones SE, Weedon MN, Shields BM, Oram RA, Hattersley AT. Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes Endocrinol. 2018 Feb;6(2):122-9. DOI: 10.1016/S2213-8587(17)30362-5.
Thunander M, Petersson C, Jonzon K, et al. Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. Diabetes Res Clin Pract. 2008 Nov;82(2):247-55. DOI: 10.1016/j.diabres.2008.07.022.
Hawa MI, Kolb H, Schloot N, et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care. 2013 Apr;36(4):908-13. DOI: 10.2337/dc12-0931.
Hampe CS, Shojaie A, Brooks-Worrell B, et al. GAD65Abs are not associated with beta-cell dysfunction in patients with t2d in the GRADE study. J Endocr Soc. 2024 Jan 16;8(3):bvad179. DOI: 10.1210/jendso/bvad179.
Pilla SJ, Balasubramanyam A, Knowler WC, et al. Islet autoantibody positivity in overweight and obese adults with type 2 diabetes. Autoimmunity. 2018 Dec; 51(8):408-16. DOI: 10.1080/08916934.2018.1547711.
Turner R, Stratton I, Horton V, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet. 1997 Nov 1;350(9087):1288-93. DOI: 10.1016/s0140-6736(97)03062-6.
Davis AK, DuBose SN, Haller MJ, et al. Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care. 2015 Mar;38(3):476-81. DOI: 10.2337/dc14-1952.
Zampetti S, Campagna G, Tiberti C, et al. High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7). Eur J Endocrinol. 2014 Dec;171(6):697-704. DOI: 10.1530/EJE-14-0342.
Leete P, Willcox A, Krogvold L, et al. Differential insulitic profiles determine the extent of beta-cell destruction and the age at onset of type 1 diabetes. Diabetes. 2016 May;65(5):1362-9. DOI: 10.2337/db15-1615.
Parviainen A, Harkonen T, Ilonen J, But A, Knip M, Finnish Pediatric Diabetes R. Heterogeneity of type 1 diabetes at diagnosis supports existence of age-related endotypes. Diabetes Care. 2022 Apr 1;45(4):871-9. DOI: 10.2337/dc21-1251.
Arif S, Leete P, Nguyen V, et al. Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. Diabetes. 2014 Nov;63(11):3835-45. DOI: 10.2337/db14-0365.
Redondo MJ, Morgan NG. Heterogeneity and endotypes in type 1 diabetes mellitus. Nat Rev Endocrinol. 2023 Sep;19(9):542-54. DOI: 10.1038/s41574-023-00853-0.
Battaglia M, Ahmed S, Anderson MS, et al. Introducing the endotype concept to address the challenge of disease heterogeneity in type 1 diabetes. Diabetes Care. 2020 Jan;43(1):5-12. DOI: 10.2337/dc19-0880.
American Diabetes Association Professional Practice C. 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025. Diabetes Care. 2025 Jan 1;48(Supplement_1):S27-49. DOI: 10.2337/dc25-S002.
Vehik K, Lynch KF, Schatz DA, et al. Reversion of beta-cell autoimmunity changes risk of type 1 diabetes: TEDDY study. Diabetes Care. 2016 Sep;39(9):1535-42. DOI: 10.2337/dc16-0181.
Phillip M, Achenbach P, Addala A, et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetes Care. 2024 Aug 1;47(8):1276-98. DOI: 10.2337/dci24-0042.
Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015 Aug 7;14:100. DOI: 10.1186/s12933-015-0260-x.
Ahlqvist E, Storm P, Karajamaki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018 May;6(5):361-9. DOI: 10.1016/S2213-8587(18)30051-2.
Lampasona V, Petrone A, Tiberti C, et al. Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: Non Insulin Requiring Autoimmune Diabetes (NIRAD) 4. Diabetes Care. 2010 Jan;33(1):104-8. DOI: 10.2337/dc08-2305.
Lampasona V, Pittman DL, Williams AJ, et al. Islet autoantibody standardization program 2018 workshop: interlaboratory comparison of glutamic acid decarb-oxylase autoantibody assay performance. Clin Chem. 2019 Sep;65(9):1141-52. DOI: 10.1373/clinchem.20-19.304196.
Mishra R, Chesi A, Cousminer DL, et al. Relative contribution of type 1 and type 2 diabetes loci to the genetic etiology of adult-onset, non-insulin-requiring autoimmune diabetes. BMC Med. 2017 Apr 25;15(1):88. DOI: 10.1186/s12916-017-0846-0.
Diabetes C, Complications Trial Research G, Nathan DM, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86. DOI: 10.1056/NEJM199309303291401.
Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003 Jun 5;348(23):2294-303. DOI: 10.1056/NEJMoa022314.
Rickels MR, Evans-Molina C, Bahnson HT, et al. High residual C-peptide likely contributes to glycemic control in type 1 diabetes. J Clin Invest. 2020 Apr 1;130(4):1850-62. DOI: 10.1172/JCI134057.
Dandona P, Chaudhuri A, Ghanim H. Semaglutide in early type 1 diabetes. N Engl J Med. 2023 Sep 7;389(10):958-9. DOI: 10.1056/NEJMc2302677.
Ramos EL, Dayan CM, Chatenoud L, et al. Teplizumab and beta-cell function in newly diagnosed type 1 diabetes. N Engl J Med. 2023 Dec 7;389(23):2151-61. DOI: 10.1056/NEJMoa2308743.
Hawa MI, Thivolet C, Mauricio D, et al. Metabolic syndrome and autoimmune diabetes: action LADA 3. Diabetes Care. 2009 Jan;32(1):160-4. DOI: 10.2337/dc08-1419.
Jacobsen LM, Vehik K, Veijola R, et al. Heterogeneity of DKA incidence and age-specific clinical characteristics in children diagnosed with type 1 diabetes in the TEDDY study. Diabetes Care. 2022 Mar 1;45(3):624-33. DOI: 10.2337/dc21-0422.
Redondo MJ, Sosenko J, Libman I, et al. Single islet autoantibody at diagnosis of clinical type 1 diabetes is associated with older age and insulin resistance. J Clin Endocrinol Metab. 2020 May 1;105(5). DOI: 10.1210/clinem/dgz296.
Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for man-agement. Nat Rev Endocrinol. 2017 Nov;13(11):674-86. DOI: 10.1038/nrendo.2017.99
Buzzetti R, Tuomi T, Mauricio D, et al. Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel. Diabetes. 2020 Aug 26. DOI: 10.2337/dbi20-0017.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 SMART-MD Journal of Precision Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Journal information